Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become…
Infex appoints Lonza to manufacture new lung infection drug
Alderley Park, Cheshire Infex Therapeutics has awarded a £1m contract to Lonza…
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Alderley Park, Cheshire Infex Therapeutics has appointed Pharmaron to help…
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to…
Infex Therapeutics and LifeArc in Collaboration to Defeat Superbugs
Infex Therapeutics has combined forces with medical research charity, LifeArc,…
Introducing Infex Therapeutics
The organisation leading UK efforts to tackle the health crisis around our…
Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award
The AMR Centre has combined forces to attract much needed investment to…